Literature DB >> 27490088

Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy.

Cong Luo1, Jin Sun2, Dan Liu3, Bingjun Sun1, Lei Miao4, Sara Musetti4, Jing Li3, Xiaopeng Han1, Yuqian Du1, Lin Li1, Leaf Huang4, Zhonggui He1.   

Abstract

Chemotherapeutic efficacy can be greatly improved by developing nanoparticulate drug delivery systems (nano-DDS) with high drug loading capacity and smart stimulus-triggered drug release in tumor cells. Herein, we report a novel redox dual-responsive prodrug-nanosystem self-assembled by hydrophobic small-molecule conjugates of paclitaxel (PTX) and oleic acid (OA). Thioether linked conjugates (PTX-S-OA) and dithioether inserted conjugates (PTX-2S-OA) are designed to respond to the redox-heterogeneity in tumor. Dithioether has been reported to show redox dual-responsiveness, but we find that PTX-S-OA exhibits superior redox sensitivity over PTX-2S-OA, achieving more rapid and selective release of free PTX from the prodrug nanoassemblies triggered by redox stimuli. PEGylated PTX-S-OA nanoassemblies, with impressively high drug loading (57.4%), exhibit potent antitumor activity in a human epidermoid carcinoma xenograft. This novel prodrug-nanosystem addresses concerns related to the low drug loading and inefficient drug release from hydrophobic prodrugs of PTX, and provides possibilities for the development of redox dual-sensitive conjugates or polymers for efficient anticancer drug delivery.

Entities:  

Keywords:  Paclitaxel; prodrug nanoparticles; redox dual-responsive; single thioether; small-molecule prodrug

Mesh:

Substances:

Year:  2016        PMID: 27490088      PMCID: PMC5541379          DOI: 10.1021/acs.nanolett.6b01632

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  23 in total

Review 1.  Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.

Authors:  Cong Luo; Jin Sun; Bingjun Sun; Zhonggui He
Journal:  Trends Pharmacol Sci       Date:  2014-10-16       Impact factor: 14.819

Review 2.  Nanotechnology in cancer therapy.

Authors:  Burcu Aslan; Bulent Ozpolat; Anil K Sood; Gabriel Lopez-Berestein
Journal:  J Drug Target       Date:  2013-09-30       Impact factor: 5.121

3.  Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

Authors:  A Y Bedikian; R C DeConti; R Conry; S Agarwala; N Papadopoulos; K B Kim; M Ernstoff
Journal:  Ann Oncol       Date:  2010-09-20       Impact factor: 32.976

Review 4.  Prodrug-based intracellular delivery of anticancer agents.

Authors:  L Bildstein; C Dubernet; P Couvreur
Journal:  Adv Drug Deliv Rev       Date:  2011-01-13       Impact factor: 15.470

Review 5.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

6.  Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.

Authors:  Antonio C Wolff; Ross C Donehower; M Katherine Carducci; Michael A Carducci; Julie R Brahmer; Yelena Zabelina; Matthews O Bradley; Forrest H Anthony; Charles S Swindell; Philip A Witman; Nigel L Webb; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Heterogeneity of glutathione content in human ovarian cancer.

Authors:  F Y Lee; A Vessey; E Rofstad; D W Siemann; R M Sutherland
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

8.  Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery.

Authors:  Simona Mura; Fatima Zouhiri; Stephanie Lerondel; Andrei Maksimenko; Julie Mougin; Claire Gueutin; Davide Brambilla; Joachim Caron; Eric Sliwinski; Alain Lepape; Didier Desmaele; Patrick Couvreur
Journal:  Bioconjug Chem       Date:  2013-10-17       Impact factor: 4.774

9.  Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.

Authors:  M Harries; A O'Donnell; M Scurr; S Reade; C Cole; I Judson; A Greystoke; C Twelves; S Kaye
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

10.  Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines.

Authors:  Yongjun Wang; Dan Liu; Qingchuan Zheng; Qiang Zhao; Hongjuan Zhang; Yan Ma; John K Fallon; Qiang Fu; Matthew T Haynes; Guimei Lin; Rong Zhang; Dun Wang; Xinggang Yang; Linxiang Zhao; Zhonggui He; Feng Liu
Journal:  Nano Lett       Date:  2014-09-07       Impact factor: 11.189

View more
  41 in total

1.  Regulating the alky chain length of fatty acid-didanosine prodrugs and evaluating its role in albumin binding.

Authors:  Hongxiang Chen; Gang Wang; Lanzhen Sun; Huicong Zhang; Mengchi Sun; Jin Sun; Lei Shang; Cong Luo
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

2.  Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.

Authors:  Zhenbao Li; Wenjuan Zhang; Yan Gao; Rongwu Xiang; Yan Liu; Mingming Hu; Mei Zhou; Xiaohong Liu; Yongjun Wang; Zhonggui He; Yinghua Sun; Jin Sun
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

Review 3.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

4.  Tumor Microenvironment Stimuli-Responsive Polymeric Prodrug Micelles for Improved Cancer Therapy.

Authors:  Zhiqiang Zhang; Miao Yu; Tong An; Jun Yang; Meijuan Zou; Yinglei Zhai; Wei Sun; Gang Cheng
Journal:  Pharm Res       Date:  2019-12-10       Impact factor: 4.200

5.  Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfide bond bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy.

Authors:  Huiyun Zhang; Wenqian Xu; Emmanuel Omari-Siaw; Yingkun Liu; Baoding Chen; Deyu Chen; Jiangnan Yu; Ximing Xu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 6.  Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.

Authors:  Lei Zhou; Hao Wang; Yaping Li
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

Review 7.  Nanoparticulation of Prodrug into Medicines for Cancer Therapy.

Authors:  Yuezhou Zhang; Huaguang Cui; Ruiqi Zhang; Hongbo Zhang; Wei Huang
Journal:  Adv Sci (Weinh)       Date:  2021-07-29       Impact factor: 16.806

Review 8.  Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope.

Authors:  Xinyu Lou; Zhichao Chen; Zhonggui He; Mengchi Sun; Jin Sun
Journal:  Nanomicro Lett       Date:  2021-01-04

9.  Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro.

Authors:  Tingting Lang; Nuannuan Li; Jing Zhang; Yi Li; Rong Rong; Yuanlei Fu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

10.  Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.

Authors:  Wu Chen; Danlei Yu; Shi-Yong Sun; Feng Li
Journal:  Acta Biomater       Date:  2021-05-25       Impact factor: 10.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.